2
Clinical Trials associated with NUV-001Double-blind, Placebo-controlled, Ascending Single- and Multiple- Dose Study of the Safety, Tolerability, and Pharmacokinetics of NUV001 Administered Orally to Healthy Adult Participants
This blinded placebo-controlled study is designed to evaluate the safety, tolerability, and PK in healthy participants of a single- and multiple-doses (SAD and MAD) of a new investigational drug: NUV001
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate Safety and Efficacy of Orally administered NUV001 nutraceutical supplement in Sickle Cell Disease (SCD) patients.
Start Date15 Sep 2022 |
Sponsor / Collaborator- |
100 Clinical Results associated with NUV-001
100 Translational Medicine associated with NUV-001
100 Patents (Medical) associated with NUV-001
100 Deals associated with NUV-001